嘧啶-4-甲醛 | 2435-50-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 嘧啶-4-甲醛
• 中文别名: 4-嘧啶甲醛
• 英文名称: pyrimidine-4-carboxaldehyde
• 英文别名: pyrimidine-4-carbaldehyde；Pyrimidin-aldehyd-(4)；pyrimidine-4-yl formaldehyde
• CAS: 2435-50-9
• 化学式: C₅H₄N₂O
• 分子量: 108.1
• InChiKey: OKULHRWWYCFJAB-UHFFFAOYSA-N

物化性质

• 沸点：
  225.3±13.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  3
• 海关编码：
  2933599090
• 危险性防范说明：
  P280,P302+P352,P304+P340,P305+P351+P338,P312
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  温度：2-8°C，惰性气体氛围

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Pyrimidine-4-carboxaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Pyrimidine-4-carboxaldehyde
CAS number: 2435-50-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H4N2O
Molecular weight: 108.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

嘧啶-4-甲醛是一种醛类衍生物，常用于制药工业作为医药中间体。

反应信息

• 作为反应物：
  描述：

  嘧啶-4-甲醛 以35%的产率得到syn-4-Hydroximinomethyl-pyrimidin
  参考文献：
  名称：

  ISOXAZOLO-PYRIDAZINE DERIVATIVES

  摘要：

  这项发明涉及异氧唑吡啶嗪化合物，特别是如上所述的式I化合物及其药用盐，具有亲和力和选择性结合到GABA A α5受体结合位点，其制备方法，含有它们的药物组合物以及它们作为认知增强剂或用于治疗认知障碍如阿尔茨海默病。

  公开号：

  US20090143385A1
• 作为产物：
  描述：

  4-甲基嘧啶 在 叔丁基过氧化氢 、 selenium(IV) oxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以72%的产率得到嘧啶-4-甲醛
  参考文献：
  名称：

  在叔丁基过氧化氢存在下，二氧化硒对 N-杂芳族化合物活性甲基的氧化作用得到改善

  摘要：

  在二恶烷中存在叔丁基过氧化氢的情况下，使用SeO 2 对包括双环和单环化合物在内的N-杂芳族化合物的活性甲基的氧化得到显着改善，从而以中等至良好的产率得到相应的醛或羧酸。与没有叔丁基过氧化氢的常规SeO 2 氧化相比，本氧化进行更温和和更有选择性地形成醛而不是羧酸。

  DOI：

  10.3987/com-02-9702

文献信息

• [EN] INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR<br/>[FR] INHIBITEURS DE PRÉSENTATION D'ANTIGÈNE PAR HLA-DR
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021198283A1

  公开（公告）日：2021-10-07

  Chromanone compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the inhibition of antigen presentation by HLA-DR.

  Chromanone化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与HLA-DR抗原呈递抑制相关的疾病状态、疾病和症状的方法。
• Facile, One-Step Production of Niacin (Vitamin B3) and Other Nitrogen-Containing Pharmaceutical Chemicals with a Single-Site Heterogeneous Catalyst
  作者：Robert Raja、John Meurig Thomas、Michael Greenhill-Hooper、Steven V. Ley、Filipe A. Almeida Paz

  DOI：10.1002/chem.200701679

  日期：2008.3.7

  Niacin (3-picolinic acid), which is extensively used as vitamin B3 in foodstuffs and as a cholesterol-lowering agent, along with other oxygenated products of the picolines, 4-methylquinoline, and a variety of pyrimidines and pyridazines, may be produced in a single-step, environmentally benign fashion by combining single-site, open-structure, heterogeneous catalysts with a solid source of active oxygen

  可以在食品中生产烟酸（3-吡啶甲酸），广泛用作食品中的维生素B3和降胆固醇剂，以及甲基吡啶，4-甲基喹啉和其他嘧啶和哒嗪的其他氧化产物。通过在不存在有机溶剂的情况下，将单中心，开放结构的多相催化剂与活性氧的固体来源（即乙酰过氧硼酸盐（APB））结合使用，从而实现对环境友好的一步式生产。这种单中心非均相催化剂所具有的高活性，选择性和相对温和的条件，以及易于运输，储存和固体氧化剂的稳定性，为APB与其他开放式结构的未来使用预示了良好的前景。 ，适用于精细化工，制药和农业化学应用的单中心催化剂。
• Substituted alkylamine derivatives and methods of use
  申请人：Amgen Inc.

  公开号：US20030225106A1

  公开（公告）日：2003-12-04

  Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的胺对预防治疗疾病有效，如血管生成介导的疾病。本发明包括新的化合物、类似物、前药和药用可接受的盐，药物组合物和预防治疗疾病和其他疾病或状况的方法，包括癌症等。本发明还涉及制造这类化合物的过程以及在此类过程中有用的中间体。
• [EN] NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2021105474A1

  公开（公告）日：2021-06-03

  The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及用于治疗与DUX4表达相关疾病的化合物，如肌肉萎缩症。它还涉及使用这些化合物，或者使用这些化合物的方法。
• Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors
  作者：Li-Min Zhao、Zhen Guo、Yi-Jie Xue、Jun Min、Wen-Jing Zhu、Xiang-Yu Li、Hu-Ri Piao、Cheng Jin

  DOI：10.3390/molecules23123369

  日期：——

  The transforming growth factor-β (TGF-β), in which overexpression has been associated with various diseases, has become an attractive molecular target for the treatment of cancers. Thirty-two quinoxaline-derivatives of 3-substituted-4-(quinoxalin-6-yl) pyrazoles 14a–d, 15a–d, 16a–d, 17a–d, 18a–d, 19a–d, 25a, 25b, 25d, 26a, 26b, 26d, 27b, and 27d were synthesized and evaluated for their activin TGF-β type I receptor kinase and p38α mitogen activated protein (MAP) kinase inhibitory activity in enzymatic assays. Among these compounds, the most active compound 19b inhibited TGF-β type I receptor kinase phosphorylation with an IC50 value of 0.28 µM, with 98% inhibition at 10 µM. Compound 19b also had good selectivity index of >35 against p38α MAP kinase, with 9.0-fold more selective than clinical candidate, compound 3 (LY-2157299). A molecular docking study was performed to identify the mechanism of action of the synthesized compounds and their good binding interactions were observed. ADMET prediction of good active compounds showed that these ones possess good pharmacokinetics and drug-likeness behavior.

  转化生长因子-β（TGF-β）已与各种疾病相关联，因此已成为治疗癌症的一种吸引人的分子靶点。合成了32种3-取代-4-(喹喔啉-6-基)吡唑类衍生物14a–d、15a–d、16a–d、17a–d、18a–d、19a–d、25a、25b、25d、26a、26b、26d、27b和27d，并在酶活性测定中评估它们对活化素TGF-β类型I受体激酶和p38α丝裂原活化蛋白（MAP）激酶的抑制活性。在这些化合物中，最活跃的化合物19b以IC50值为0.28 µM抑制了TGF-β类型I受体激酶的磷酸化，在10 µM时抑制率达到98%。化合物19b对p38α MAP激酶也具有良好的选择性指数，对比临床候选化合物3（LY-2157299）具有9.0倍的选择性。进行了分子对接研究以确定合成化合物的作用机制，并观察到它们良好的结合相互作用。对良好活性化合物的ADMET预测显示，这些化合物具有良好的药代动力学和药物样性行为。